Controlled human infection models in vaccine development: what’s new in 2025?

Controlled human infection models (CHIMs) can be a powerful tool for generating dosing, safety, and efficacy data throughout the vaccine development process, from early development to licensure. CHIMs can speed up development by rapidly eliminating unsuccessful candidates and de-risking later clinical trials. They are also invaluable when opportunities for field trials are limited.

These benefits have led to increased interest in CHIMs, including expanding their use in endemic and low-resource settings. However, to unlock their full potential, vaccine developers must navigate ethical and safety concerns, regulatory hurdles, and selection and sourcing of appropriate models.

Vaccine Insights assembled a panel of leading experts from academia, pharma, and regulatory bodies to discuss the opportunities and challenges for CHIM studies in 2025 and beyond.

Please enter your email to access content Read now